Xiaoning Shen

Title: Innovations of Xiaoning Shen in Biopharmaceuticals

Introduction

Xiaoning Shen is a prominent inventor based in Shanghai, China, known for his significant contributions to the field of biopharmaceuticals. He holds three patents that showcase his innovative work in antibody development and disease treatment.

Latest Patents

One of his latest patents is an anti-interleukin-4 receptor (IL-4R) single-domain antibody, which includes a coding polynucleotide and methods for its use in IL-4R detection and disease treatment. This invention details a single-domain antibody that specifically recognizes human and marmoset IL-4R, while not recognizing mouse IL-4R, demonstrating excellent specificity. The antibody effectively inhibits the proliferation of TF-1 cells and the activation of the pSTAT6 signaling pathway in cells. Another notable patent is for a blocking type PD-L1 single-domain camel antibody, which can be utilized for treating, preventing, or diagnosing PD-L1 related diseases, including tumors.

Career Highlights

Xiaoning Shen is currently associated with Shanghai Novamab Biopharmaceuticals Co., Ltd., where he continues to advance his research and development efforts in the biopharmaceutical sector. His work has positioned him as a key figure in the innovation of therapeutic antibodies.

Collaborations

He collaborates with notable colleagues, including Yakun Wan and Min Zhu, contributing to a dynamic research environment that fosters innovation and discovery.

Conclusion

Xiaoning Shen's innovative work in the development of therapeutic antibodies highlights his significant impact on the biopharmaceutical industry. His patents reflect a commitment to advancing medical science and improving treatment options for various diseases.